Serum ferritin levels and endocrine disorders in children with thalassemia major

Evi Dewiyanti, Aditiawati, Dian Puspita Sari

Abstract
Background. Endocrine disorders in thalassemia major children occur due to iron overload and hemosiderosis in endocrine organs. Early detection is needed to prevent complications and improve the quality of life. An association between serum ferritin and endocrine disorders in thalassemia patients has been inconclusive to date.

Objective. To analyze for possible associations between serum ferritin and endocrine disorders (short stature, delayed puberty, delayed bone age, hypothyroidism, impaired glucose tolerance, and diabetes mellitus) and the incidence of each disorder in thalassemia major.

Methods. There were 115 thalassemia major patients aged 10-18 years involved in our cross-sectional study from June 2019 - June 2020 in the Pediatrics Department, DR. M. Hosein Hospital, Palembang, South Sumatera. Anthropometry and socioeconomic status information were collected from physical examination and interview. Ferritin, FT4, TSH, Hb and glucose levels measured by using standard methods for each item in the laboratory, mean while the skeletal age assessment was determined by using FELS method.

Results. This study included 83 (72.2%) girls and 32 (27.8%) boys. There were 89 (77.4%) subjects with short stature, 74 (64.4%) with delayed bone age, 30 (26.1%) with impaired glucose tolerance, 25 (21.7%) with delayed puberty, 4 (3.5%) with diabetes mellitus (DM), and none with hypothyroidism. Bivariate and multivariate analyses revealed no associations between serum ferritin and short stature, delayed bone age, impaired glucose tolerance, delayed puberty, and DM.

Conclusion. There is a high prevalence of endocrine disorders in pediatric thalassemia patients, especially short stature and delayed bone age. However, there are no associations between serum ferritin and endocrine disorders in these patients. [Paediatr Indones. 2021;61:125-32 ; DOI: 10.14238/pi61.3.2021.125-32 ].

Keywords: association; thalassemia major; children; ferritin; complications; endocrine disorders
in order to excrete the iron through the urine or feces.\textsuperscript{4-7}

Some common endocrine complications of thalassemia are short stature, gonadotropin hypogonadism, delayed puberty, impaired glucose tolerance, hypothyroidism, hypoparathyroidism, and diabetes mellitus. Complications may also occur in non-endocrine organs, such as the heart, kidneys, bones, eyes, and other organs.\textsuperscript{7-10}

The gold standard to determine tissue iron level is a tissue biopsy. Serum ferritin is considered to be representative of iron overload and hemosiderosis, and has been used in past studies of endocrine disorders. The prevalence of thalassemic endocrine disorders was reported to range from 34\% to 92\%.\textsuperscript{11-15} Early detection of endocrine complications in thalassemic patients is needed to improve their quality of life. The aim of this study was to analyze for possible associations between serum ferritin and endocrine disorders (short stature, delayed puberty, delayed bone age, hypothyroidism, impaired glucose tolerance, and diabetes mellitus) and the incidence of each disorder in thalassemia major.

Methods

This cross-sectional study was conducted from June 2019-June 2020 at the Pediatrics Department, Dr. Moh. Hosein Hospital, Palembang, South Sumatera, in thalassemia major patients aged 10-18 years who underwent routine blood transfusions and received iron chelation treatments. Patients taking high-dose steroids for two weeks or more were excluded from this study. The subjects were included by consecutive sampling. Patients and families provided written informed consent for study inclusion. Data were obtained from interviews, as well as physical, laboratory, and radiology support examinations.

Short stature was defined as a height more than two standard deviations below the mean for age (less than the 3rd percentile) CDC curve. Subject was categorized as having a delayed puberty if she/he showed the lack of any pubertal signs by the age of 13 years in girls and 14 years in boys. A decreased rate of skeletal maturation was classified as retarded bone age and can be diagnosed on the basis of an estimation of the bone age from radiographs of specific bones in the human body. Diabetes mellitus and impaired glucose intolerance was diagnosed based on International Society of Pediatric and Adolescent Diabetes (ISPAD) 2018.\textsuperscript{16} Hypothyroid was defined as having FT4 level < 0.7 ng/dL.

Serum ferritin levels from venous blood was measured using a turbidimetric method by the hospital laboratory staff in units of ug/L. The nutritional status was determined based on percentage of weight for height (WFH) in CDC criteria; severely undernourished (if WFH <70\%), undernourished (if WFH 70-90\%), well nourished (if WFH 90-110\%) and overnourished (if WFH >110\%). Endocrine disorders were reported as a percentage, while numerical data were reported as

\begin{table}
\centering
\caption{Characteristics and hematological profiles of subjects}
\begin{tabular}{ll}
\hline
Characteristics & (N=115) \\
\hline
Gender, n (%) & \\
Male & 32 (27.8)
Female & 83 (72.2)

Median age, months (range) & 168 (120-216)

Nutritional status, n (%) & \\
Severely undernourished & 2 (1.7)
Undernourished & 28 (24.3)
Well-nourished & 82 (71.3)
Overnourished & 3 (2.6)

Median age at diagnosis (range), months & 54 (3-188)

Median duration of illness (range), months & 108 (4-213)

Median pre-transfused Hb (range), gr/dL & 7.4 (4.1-11.7)

Pre-transfused Hb, n (%) & \\
<9 g/dL & 102 (88.7)
≥9 g/dL & 13 (11.3)

Frequency of transfusion, n (%) & \\
≥ 2 times/month & 19 (16.6)
< 2 times/month & 96 (83.4)

Type of chelation agent, n (%) & \\
Deferiprone & 102 (88.7)
Deferasirox & 13 (11.3)

Median duration of chelating therapy (range), months & 84 (3-192)

Duration of chelating therapy, n (%) & \\
≤ 84 months & 64 (55.5)
> 84 months & 51 (44.5)

Median ferritin level (range), ng/dL & 3,761 (102-78760)

Ferritin levels, n (%) & \\
<1,000 ng/dL & 7 (6.1)
1,001-5,000 ng/dL & 70 (60.9)
5,001-10,000 ng/dL & 31 (27)
>10,000 ng/dL & 7 (6.1)
\hline
\end{tabular}
\end{table}
median (abnormally distributed).

This study was approved by the Ethics Committee of Universitas Sriwijaya Medical School/Dr. Moh. Hoesin Hospital, Palembang, South Sumatera. Data analysis was performed by using SPSS version 22 and Microsoft Excel 2007. The results were considered significant for P values <0.05, with a confidence interval of 95%.

Results

There were 115 thalassemia patients included in our study, 83 girls and 32 boys. Most subjects had good nutritional status and received deferiprone as a chelating agent. Subjects’ median age at diagnosis was 54 months, duration of illness was 108 months, pre-transfusion Hb was < 9 g/dL (Table 1). Eighty-nine (77.4%) subjects had short stature, 25 (21.7%) had delayed puberty, 74 (64.4%) had retarded bone age, 30 (26.1%) had impaired glucose tolerance, 4 (3.5%) had DM, and none had thyroid hormone disorders (Table 2).

All study subjects suffered any of endocrine disorders, and most had ferritin levels of 1,001 to 5,000 ng/dL and 5,001-10,000 ng/dL. Seven (6%) subjects had ferritin level < 1000 ng/dL, but still had endocrine disorders (Table 3).

Bivariate and multivariate analyses revealed no associations between serum ferritin level and all endocrine disorders. For bivariate analysis, we categorized ferritin levels 1000 ng/dL (as a cutoff point for iron overload) and also cut-off point ferritin level of each endocrine disorder in this study as comparison. The ferritin cut-off points were 2,998 ng/dL for delayed puberty, 3,721 ng/dL for impaired glucose tolerance, 4,985 ng/dL for DM, 2,956 ng/dL for short stature, and 2,956 ng/dL for delayed bone age (Table 4, Table 5).

Discussion

In our study, most subjects were girls (72.2%), similar

| Parameter                        | Short stature (n=89) | Late puberty (n=25) | Retarded bone age (n=74) | DM (n=4) | Impaired glucose tolerance (n=30) |
|----------------------------------|---------------------|---------------------|---------------------------|----------|---------------------------------|
| Gender, n                        |                     |                     |                           |          |                                 |
| Males (n=32)                     | 29                  | 10                  | 19                        | 2        | 10                              |
| Females (n=83)                   | 60                  | 15                  | 55                        | 2        | 20                              |
| Transfusion frequency, n         |                     |                     |                           |          |                                 |
| < 2 times/mo                     | 75                  | 22                  | 60                        | 4        | 25                              |
| ≥ 2 times/mo                     | 14                  | 3                   | 14                        | 0        | 5                               |
| Nutritional status, n            |                     |                     |                           |          |                                 |
| Severely undernourished          | 1                   | 0                   | 2                         | 0        | 0                               |
| Undernourished                   | 24                  | 8                   | 21                        | 2        | 8                               |
| Well-nourished                   | 62                  | 17                  | 49                        | 2        | 22                              |
| Overnourished                    | 2                   | 0                   | 2                         | 0        | 0                               |
| Type of iron chelation, n        |                     |                     |                           |          |                                 |
| Deferiprone                      | 78                  | 24                  | 64                        | 3        | 28                              |
| Deferasirox                      | 11                  | 1                   | 10                        | 1        | 1                               |
| Median age (range), mo           | 168 (120-216)       | 192 (132-216)       | 168 (120-216)             | 174 (138-216) | 168 (120-216)                  |
| Median age at diagnosis (range), mo | 48 (3-188)       | 36 (3-180)          | 48 (3-180)                | 24 (8-42) | 39 (3-168)                     |
| Median duration of illness (range), mo | 108 (4-213)   | 161 (12-213)        | 51.85 (12 -213)           | 149 (114-192) | 115 (24-213)                  |
| Median duration of chelating therapy (range), mo | 84 (3-192) | 120 (12-192)        | 84                        | 168      | 96                              |
| Median pre-transfusion Hb (range), gr/dL | 7.5 (4.1-11.7)  | 7.2 (5.1-9.5)       | 7.4 (4.1-11.7)            | 6.7 (6.1-7.2)| 6.83 (4.2-10)               |
| Median serum ferritin (range), ng/dL | 3,761              | 3,200               | 4,087                     | 5,724    | 4,276                           |

Paediatr Indones, Vol. 61, No.3, May 2021 • 127
Parents had received much information about taking care of thalassemic children, both through direct education and social media. As such, parents had increased awareness of their children’s nutritional requirements, so that despite their low income, most subjects (82%) were well-nourished. Similarly, a study also found that most thalassemic children at Dr. Moh. Hoesin Hospital, Palembang, South Sumatera, had good nutrition. In contrast, another study reported higher proportions of malnutrition in their thalassemic subjects. Many factors can influence children’s nutritional status, such as individual treatments and nutritional intake.

Deferiprone and deferasirox were the iron chelatators prescribed at RSMH at this time. Irregular patient visits, mainly due to cost and time factors, affected patient adherence to consuming iron chelation and led to low pre-transfusion hemoglobin (Hb) levels and increased serum ferritin. In our study, most subjects (88.7%) had pre-transfused Hb under 9 g/dL, and 93.9% had serum ferritin >1,000 ng/dL. The prevalences of the different endocrinopathies in this study ranged from 3.5 to 77.4%. Endocrine disorders in thalassemia mostly begin at 10 years of age due to iron overload.

There were 7 subjects with ferritin levels <1,000 ng/dL, but who had endocrine disorders. Serum ferritin only represents for about 1% of the human total iron reserves and the level influenced by several factors, such as viral and bacterial infections, malignancy, inflammation, and vitamin C deficiency. Theoretically, ferritin interferes in bone metabolism through direct toxicity of osteoblasts. The high serum ferritin level may not have been due to only the frequency of transfusions, but to other factors not analyzed, such as viral or bacterial infections or vitamin C deficiency. The causes of growth disorders in thalassemia are multifactorial, including gonadotropin secretion abnormalities, chronic anemia, hypoxia, liver disease, folic acid and zinc deficiency, emotional factors, growth hormone-insulin-like factor-1 (GH-IGF1) axis disorder, and bone dysplasia induced by iron chelation therapy. As zinc is required for growth, some studies suggested that zinc supplementation may improve growth.

In our study, short stature occurred in 59.6% of subjects, and most of them (59.6%) had ferritin levels of 1,001-5,000 ng/dL. We found no association between serum ferritin levels and short stature, similar to a study from Padang, West Sumatera, concluding that ferritin levels did not affect endocrine disorders in β-thalassemia major patients. Several studies also concluded that levels of ferritin did not affect bone growth and age in thalassemia patients.

A previous study reported on growth disorders and bone age in thalassemic children. Bone histomorphometry showed osteoid thickening.

---

### Table 3. Distribution of endocrine disorders according to serum ferritin level (N = 115)

| Parameter          | Ferritin levels, ng/dL |  |  |  | P value |
|--------------------|------------------------|---|---|---|---------|
|                    | <1,000 (n=7)           | 1,001-5,000 (n=70) | 5,001-10,000 (n=31) | > 10,000 (n=7) |         |
| Glucose tolerance, n (%) | Normal | 6 (7.3) | 48 (59.3) | 22 (27.2) | 5 (6.2) | 0.888 |
|                    | Disturbed | 1 (3.3) | 20 (66.7) | 7 (23.3) | 2 (6.7) |         |
|                    | DM | 0 (0) | 2 (50) | 2 (50) | 0 (0) |         |
| Stature, n (%)     | Short | 6 (6.7) | 53 (59.6) | 23 (25.8) | 7 (7.9) | 0.455 |
|                    | Normal | 1 (3.8) | 17 (65.4) | 8 (30.8) | 0 (0) |         |
| Puberty, n (%)     | Delayed | 4 (16) | 12 (48) | 6 (24) | 3 (12) | 0.047 |
|                    | Normal | 3 (33.3) | 58 (64.4) | 25 (27.6) | 4 (4.4) |         |
| Bone age, n (%)    | Delayed | 3 (4.1) | 42 (56.8) | 23 (31.1) | 6 (8.1) | 0.196 |
|                    | Normal | 4 (9.8) | 28 (68.3) | 8 (19.5) | 1 (2.4) |         |
Table 4. Bivariate analyses of serum ferritin level and endocrine disorders

| Ferritin levels       | Endocrine disorders | N  | OR 95% CI | P value |
|-----------------------|---------------------|----|-----------|---------|
|                       | With                | Without |          |         |
| **Delayed puberty**   |                     |        |           |         |
| n(%)                  | 25 (21.7)           | 90 (78.3) |        | 0.780*  |
| Median (range)        | 3200 (102-34,270)   | 3800 (413-78,760) |  |         |
| n(%)                  | <1,000 ng/dL        | 3 (42.9) | 4 (57.1) | 7  | 0.48 (0.19 to 1.21) | 0.173** |
|                       | ≥1,000 ng/dL        | 22 (20.4) | 86 (79.6) | 108 |         |
| n(%)                  | <2,998 ng/dL        | 11 (24.4) | 34 (75.6) | 45  | 0.82 (0.41 to 1.64) | 0.573** |
|                       | ≥2,998 ng/dL        | 14 (20.0) | 56 (60.0) | 70  |         |
| **Impaired glucose tolerance** |                   |        |           |         |
| n(%)                  | 34 (29.6)           | 81 (70.4) |        |         |
| Median (range)        | 4276 (102-78760)    | 3420 (207-46806) |  |         |
| n(%)                  | <1,000 ng/dL        | 2 (28.6) | 5 (71.4) | 7   |         |
|                       | ≥1,000 ng/dL        | 32 (29.6) | 76 (70.4) | 108 |         |
| n(%)                  | <2,998 ng/dL        | 13 (22.8) | 44 (77.2) | 57  |         |
|                       | ≥2,998 ng/dL        | 21 (36.2) | 37 (63.8) | 58  |         |
| **Diabetes mellitus** |                     |        |           |         |
| n(%)                  | 4 (3.5)             | 111 (96.5) |        | 0.309 * |
| Median (range)        | 3681 (102-78760)    | 5764 (3500-7588) |  |         |
| n(%)                  | <1,000 ng/dL        | 0 (0)   | 7 (100)  | 7   | 1.04 (0.31 to 3.47) | 0.659** |
|                       | ≥1,000 ng/dL        | 4 (3.7) | 104 (96.3) | 108 |         |
| n(%)                  | <2,998 ng/dL        | 1 (1.3)  | 75 (98.7) | 76  | 1.58 (1.88 to 2.86) | 0.115*** |
|                       | ≥2,998 ng/dL        | 3 (7.7) | 36 (92.3) | 39  |         |
| **Short stature**     |                     |        |           |         |
| n(%)                  | 89 (77.4)           | 26 (22.6) |        | 0.718 * |
| Median (range)        | 3761 (102-78760)    | 3670 (649-9,719) |  |         |
| n(%)                  | <1,000 ng/dL        | 6 (85.7) | 1 (14.3) | 7   | 0.93 (0.89 to 0.98) | 0.587 ** |
|                       | ≥1,000 ng/dL        | 83 (93.3) | 25 (23.1) | 108 |         |
| n(%)                  | <2,998 ng/dL        | 33 (75.0) | 11 (25.0) | 44  | 1.05 (0.85 to 1.29) | 0.629 *** |
|                       | ≥2,998 ng/dL        | 56 (78.9) | 15 (21.1) | 71  |         |
| **Retarded bone age** |                     |        |           |         |
| n (%)                 | 74 (64.4)           | 41 (35.6) |        | 0.718 * |
| Median (range)        | 3761 (102-78760)    | 3670 (649-9,719) |  |         |
| n(%)                  | <1,000 ng/dL        | 6 (85.7) | 1 (14.3) | 7   |         |
|                       | ≥1,000 ng/dL        | 83 (93.3) | 25 (23.1) | 108 |         |
| n(%)                  | <2,998 ng/dL        | 33 (75.0) | 11 (25.0) | 44  |         |
|                       | ≥2,998 ng/dL        | 56 (78.9) | 15 (21.1) | 71  |         |

*Mann-Whitney test; **Fisher’s exact test; ***Chi-square test

and delayed maturation and mineralization of osteoids caused the matrix maturation disruption and mineralization seen along with iron accumulation. This condition could lead to delayed bone maturation and focal osteomalacia, leading to pathogenesis of bone disorders by suboptimal blood transfusions and iron overload. In this study, bivariate or multivariate analyses revealed no associations between serum ferritin...
and bone age. These results were similar with a study that showed no associations between serum ferritin and bone age.29

Most subjects with impaired glucose tolerance had ferritin levels between 1,001 and 5,000 ng/dL. Subjects with DM were distributed among the 1,001 -10,000 ng/dL ferritin groups. Pancreatic and hepatic iron overload and hemosiderosis were suggested to be responsible for insulin deficiency and resistance. Excess iron and oxidative stress lead to apoptosis and loss of pancreatic beta cells, so that the ability to secrete insulin progressively decreases, leading to glucose intolerance and diabetes. Oxidative stress alone through the Fenton reaction can cause direct damage and fibrosis of insulin receptors in the liver and muscles, which also leads to hyperinsulinemia and insulin resistance.25,30 Suvarna et al.26 concluded that fasting plasma insulin and insulin resistance index were significantly increased in thalassemia patients, even with no impaired glucose tolerance or DM. They speculated that insulin resistance had occurred before the impaired glucose tolerance and DM. A high insulin level is compensation of insulin resistance to maintain euglycemia.31 A previous study stated that ferritin affected glucose tolerance disorders.30 In contrast, we found no association between serum ferritin and impaired glucose tolerance or DM, though with a higher ferritin cut-off point than for other endocrine disorders.

Although the exact mechanism of iron overload causing tissue damage is not completely clear, some evidence suggests that free radicals and lipid peroxidases induced damage to mitochondria, lysosomes, and sarcoplasmic membranes. Iron deposits and oxidative damage caused by free radicals resulted in pituitary (especially the anterior) damage, which is very sensitive to oxidative stress produced by free radicals and follicles in the ovaries. As a consequence, disturbances in hypothalamus-pituitary axis and gonad function eventually leads to delayed puberty, despite intensive iron chelation therapy.25,32-34

In our study, the ferritin cut-off of 2,998 ng/dL was assumed to cause delayed puberty. However, 2 previous studies used ferritin cut-off points for delayed puberty at 3,000 ng/dL and 2,100 ng/dL, respectively.31,35 A study concluded that every 100-unit increase in ferritin level increased the risk of delayed puberty by 2.5%.35 We found no association between ferritin and delayed puberty. Another study also found no significant association between hypogonadism and serum ferritin levels.15

In conclusion, short stature is the most common endocrine disorder (77.4%) in thalassemic children, followed by delayed bone age (64.4%), impaired glucose tolerance (26.1%), delayed puberty (21.7%), and diabetes mellitus (3.5%). There are no thyroid hormone (hypothyroid) disorders in this study. Serum ferritin is not associated with any endocrine disorders in children with thalassemia major.

Conflict of Interest

None declared.

Funding Acknowledgment

Hematology and bone age examinations are routine examinations for thalassemia patients and covered by government health insurance (BPJS).

References

1. Eijkman Institute. Thalassemia. [cited 2020 November 3]. Available from: http://www.eijkman.go.id/units/red-blood-cell-diseases/activities/thalassemia/.
2. De Sanctis Vincenzo,Kattamis C,Canatan D,Soliman A,Yassin M, Wali Y. Beta Thalassemia distribution in the old world: an ancient disease seen from a historical standpoint. Medit J Hematol Infect Dis.. 2017;9:e2017018. DOI:10.4084/mjhid.2017.018.
3. Divisi Hemato-onkologi anak RSMH. Register pasien talasemia. Palembang: RSMH; 2018.
4. Gupta R, Musallam KM, Taher AT, Rivella S. Ineffective Erythropoiesis: Anemia and Iron Overload. Hematol
Evi Dewiyanti et al.: Serum ferritin levels and endocrine disorders in children with thalassemia major

Oncl Clin North Am. 2018;32:213-221. DOI: 10.1016/j.hoc.2017.11.009.

5. Al-Hakeim H, Abdulzahra M, Ridha M. Study of the effect of iron overload on the function of endocrine glands in male thalassemia patients. Asian J Transfus Sci. 2011;5:127. DOI: 10.4103/0973-6247.83236.

6. Taher AT, Musallam KM, Inati A. Iron overload: consequences, assessment, and monitoring. Hemoglobin. 2009;33(suppl):S46-S57. DOI: 10.3109/03630262903346676.

7. Taher AT, Saliba AN. Iron overload in thalassemia: different organs at different rates. Hematology. 2017;2017:265-271. DOI: 10.1182/asheducation-2017.1.265.

8. Al-Akhras A, Badr M, El-Safy U, Kohne E, Hassan T, Abdelrahman H, et al. Impact of genotype on endocrine complications in ß-thalassemia patients. Biomed.Rep. 2016;4:728-736. doi: 10.3892/br.2016.646.

9. De Sanctis V, Soliman A, Elsedy H, Skordis N, Kattamis C, Angastiniotis M, et al. Growth and endocrine disorders in thalassemia: The international network on endocrine complications in thalassemia (I-CET) position statement and guidelines. Indian J Endocr Metab. 2013;17:8. DOI: 10.4103/2230-8210.107808.

10. Azami M, Parizad N, Sayehmiri K. Prevalence of hypothyroidism, hypoparathyroidism and the frequency of regular chelation therapy in patients with thalassemia major in Iran: A Systematic review and meta-analysis study. Iran J Ped Hematol Oncol. 2016;6:261-76.

11. Elalfy MS, Esmat G, Matter RM, Abdel Aziz HE, Massoud WA. Liver fibrosis in young Egyptian beta-thalassemia major patients: relation to hepatitis C virus and compliance with chelation. Ann. Hepatol. 2013;12:54-61. DOI: 10.1016/S1665-2681(19)31385-7.

12. Ferdian BA, Rosdiana N, Lubis B. Impact of iron therapy on Mentzer index and red cell distribution width index in primary school children with iron deficiency anemia. Pediatr. Indones. 2009;49:195-9. DOI: 10.14238/pi49.4.2009.195-9.

13. Badfar DG, Nasirikandy DMB, Shohani DM, Mansouri A, Shabani E, Rahmati S, et al. Prevalence of short stature, underweight and delayed puberty in Iranian patients with thalassemia major: A systematic review and meta-analysis. Iran J Ped Hematol Oncol. 2017;7:15. Iran J Ped Hematol Oncol. 2017;7:245-259.

14. Al-Agha A, Shabakah SA, Ocheltree A, Abdullatif DEM, Jaouni KA. Endocrinopathies in children and adolescents with b-thalassemia major. J Appl Hematol 2011;2:20-4.

15. Chahkandi T, Norouziasl S, Farzad M, Ghadani F. Endocrine disorders in ß-thalassemia major. ijp ; Int J Pediatr. 2017;5:5531-8. DOI: 10.22038/ijp.2017.21937.1834.

16. Mayer-Davis EJ, Kahkoska AR, Jefferies C, Dabelea D, Balde N, Gong CX, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Definition, epidemiology, and classification of diabetes in children and adolescents. Pediatr Diabetes. 2018;19 (Suppl. 27):7-19. DOI: 10.1111/pedi.12773.

17. Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis. 2010;5:11. DOI: 10.1186/1750-1172-5-11.

18. Angastiniotis M, Linos S. Thalassemias: An Overview. IJNS. 2019;5:16. DOI: 10.3390/ijns5010016.

19. Jaya IK, Sari DP, Zen NF. Gambaran usia tulang pada pasien talasemia dengan perawakan pendek di bagian ilmu kesehatan anak RSUP Dr. Moh Hoesin Palembang. Jurnal Kedokteran dan Kesehatan FK UNSRI. 2015:2:217-22.

20. Putri DM, Oenzil F, Efriida E. Gambaran status gizi anak talasemia ß mayor di RSUP D. M Djamil Padang. Jurnal Kesehatan Andalas. 2015:4. DOI: 10.25077/jka.v4i3.367.

21. Ayudhia S, Rini EA. Gangguan Endokrin pada Pasien Thalasemia ß mayor di RSUP M Djamil Padang. Human Care. 2020;5:554. DOI: 10.32883/hcj.v5i2.708.

22. Sherief LM, Abd El-Salam SM, Kamal NM, El Safy O, Amlalky MAA, Azab SF, et al. Nutritional Biomarkers in Children and Adolescents with Beta-Thalassemia-Major: An Egyptian Center Experience. Biomed Res. Int. 2014;2014:1-7. DOI: 10.1155/2014/261761.

23. Mahachoklertwattana P, Sirikulchayanonta V, Chuansumrit A, Karnsombat P, Choutrum L, Sripriapradang A, et al. Bone histomorphometry in children and adolescents with ß-Thalassemia disease: iron-associated focal osteomalacia. J. Clin. Endocrinol. Metab. 2003;88:3966-72. DOI: 10.1210/jc.2002-021548.

24. Elalfy MS, Saber MM, Adly AAM, Ismail EA, Tarif M, Ibrahim F, et al. Role of vitamin C as an adjuvant therapy to different iron chelators in young ß-thalassemia major patients: efficacy and safety in relation to tissue iron overload. Eur J Haematol. 2016;96:318-26. DOI: 10.1111/ejh.12594.

25. Indrasari ND, Timan IS, Wahidiyat PA. Difference of collagen IV in liver damage and hepatitis C infection in iron overload thalassemia patients. Indonesian J Clin Pathol Med Lab. 2015;22:1-8.

26. Suvarna J, Ingle H, Deshmukh CT. Insulin resistance and beta cell function in chronically transfused patients of thalassemia Major. Indian Pediatr. 2006;43:8. PMID: 16735760.

27. Erdoğan E, Canatan D, Örmeci AR, Vural H, Aylak F. The effects of chelators on zinc levels in patients with thalassemia major. J. Trace Elem. Med. Biol. 2013;27:109-11. DOI: 10.1016/j.jtemb.2012.10.002.

28. Mojtahedzadeh F, Kosaryan M, Mahdavi M-R, Akbari J. The effect of folic acid supplementation in beta thalassemia major: Paediatr Indones, Vol. 61, No.3, May 2021 • 131
29. Andayani SH, Sekarwana N, Fadil R. Association between age and serum ferritin level with bone age deficit in children with thalassemia major. Paediatr Indones. 2008;48:33-6. DOI:10.14238/pi48.1.2008.33-6.

30. Chern JPS, Lin KH, Lu MY, Lin DT, Lin KS, Chen JD, et al. Abnormal Glucose Tolerance in Transfusion-Dependent -Thalassemic Patients. Diabetologia. 2001;44:850-4. DOI: 10.1007/s001250100371.

31. Shalitin S, Carmi D, Weintorb N, Phillip M. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients. Eur J Haematol. 2005;74:93-100. DOI: 10.1111/j.1600-0609.2004.00371.x.

32. Anderson CP, Shen L, Einstein R, Leibold E. Mammalian iron metabolism and its control by iron regulatory proteins. Biochim Biophys Acta. 2012;1823:1468-83. DOI: 10.1016/j.bbamcr.2012.05.010.

33. Batubara JR, Akib A, Pramita D. Delayed puberty in thalassemia major patients. Paediatr Indones. 2016;44:143-7. DOI: 10.14238/pi44.4.2004.143-7.

34. Tesorierie L, D’Arpa D, Butera D, Allegra M, Renda D, Maggio A, et al. Oral supplements of vitamin E improve measures of oxidative stress in plasma and reduce oxidative damage to LDL and erythrocytes in β-thalassemia intermedia patients. Free Radic. Res. 2001;34:529-40. DOI: 10.1080/10715760100300461.

35. Seyed Eshaq-Hoseini SK, Jafari-Koshki T, Arsang-Jang Shapouri J. Endocrinopathy complications and the role of serum ferritin as a marker of endocrinopathy prediction in patients with beta-thalassemia major. Adv Hum Biol 2018;8:169-74. DOI: 0.4103/AIHB.AIHB_18_18.